Axitinib is an inhibitor of tyrosine kinase vascular endothelin growth factor receptors 1-3. ABC and SLC transport properties of axitinib were determined in selected cellular systems. Axitinib exhibited high passive permeability in all cell lines evaluated (Papp did not pose a risk for systemic drug interactions with P-gp or BCRP per regulatory guidance.
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Introduction
Axitinib (AG-013736), N-methyl-2-[[3-[(1E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
), is an orally dosed inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, 2 and 3 (Hu-Lowe et al., 2008) . The VEGFR regulates angiogenesis, which is the formation of new blood vessels from the existing vasculature. New blood vessels are necessary for rapid tumor growth (Folkman et al., 1971) . Most solid tumors in breast, lung, renal, colorectal and liver tissues express high levels of VEGFR compared to normal tissues (Hanahan and Folkman, 1996) . The mechanism of action for VEGFR inhibitors, such as axitinib, is to reduce vascularization of solid tumors, and consequently, minimize tumor growth. A phase I clinical trial investigated the tolerability, pharmacokinetics and clinical activity of axitinib (Rugo et al., 2005) . The dose limiting toxicities were elevated blood pressure (an extension of pharmacology), hemoptysis, and stomatitis. Pharmacokinetics were studied over an oral dose range from 2 -20 mg twice daily and T max and half-life ranged from 1.7-6.0 hr and 1.7-4.8 hr, respectively. Axitinib produced confirmed partial responses in three patients and a dose of 5 mg twice daily was selected for phase II studies. In subsequent clinical trials, axitinib was active in cancers of the kidney (Rixe et al., 2007) and thyroid (Cohen et al., 2008) . A multicenter international phase III clinical trial confirmed that axitinib was well tolerated with a similar adverse event profile as sorafenib, demonstrating a significant increase in progression free survival in advanced renal cell carcinoma (RCC) patients compared to sorafenib (Rini et al., 2011) . In early 2012, axitinib received approval for treatment of advanced RCC in patients who failed one prior systemic therapy by the United States Food and Drug Administration.
Axitinib is a member of the tyrosine kinase inhibitors (TKIs) which, as a class, have similarities in absorption, metabolism and transport characteristics. Many (but not all) have DMD #51193
good to complete absorption with fraction absorbed values greater than 0.3 with some in the 0.6 to 1.0 range (Hartmann et al., 2009) . Most are substrates for cytochrome P450s and the efflux transporters, P-gp and BCRP. Axitinib is metabolized primarily by cytochrome P450 (CYP3A) with minor contributions from CYP1A2, CYP2C19, and UGT1A1 (Zientek, 2010; . Metabolism and efflux may contribute to the variable absorption, distribution and elimination of these medicines. Focusing on the transporter aspect, tyrosine kinase inhibitors (such as imatinib, erlotinib, sunitinib and lapatinib) are inhibitors of efflux transporters (P-gp and BCRP) and, to varying degrees, interact with organic anion-transporting polypeptides (OATP), organic anion transporters (OAT), organic cation transporters (OCT), and carnitine/organic cation transporter (OCTN) (van Erp et al., 2009; Dohse et al., 2010) . OATP transporters can be rate limiting in the clearance of drugs (Shimizu et al., 2005) and may contribute to patient variability especially if OATP1B1 is involved due to polymorphisms associated with this hepatic uptake transporter (Nishizato et al., 2003) . The aim of this work was to investigate the role of efflux and uptake transporters in the disposition and drug interaction potential of axitinib. Poller et al. (2011) previously demonstrated that axitinib is a substrate for P-gp and BCRP in rodent knockout and cell-based in vitro models . Early studies conducted in our lab suggested differing results for these efflux transporters and the work herein attempts to understand this discrepancy as well as to examine other transporter-related characteristics. Also, with ongoing interest in DDI potentials relating to P-gp efflux and the significance of these effects, proposals utilizing modeling and simulation are beginning to be included in regulatory filings for new drugs. We examined GastroPlus TM , a drug absorption and physiologic-based pharmacokinetic modeling and simulation software program in this work to better understand the pH-dependent solubility of axitinib and how this characteristic may relate to the DDI potential.
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experimental conditions and at equilibrium were determined in HBSS transport buffer in the presence of 0.5 or 1% DMSO. Axitinib was added to HBSS transport buffer in DMSO at a concentration of 10 µM and incubated at 37°C for 3 hours for simulated use. Equilibrium solubility in HBSS buffer was determined by adding 1 mg axitinib to 2 mL HBSS containing either 0.5 or 1% DMSO and incubating at 37°C for 2-3 days. Following the incubation the samples were centrifuged to separate undissolved drug and the solution concentration of axitinib determined by HPLC/UV. Equilibrium solubility determinations were assessed over a range of pH values to generate input values for GastroPlus™. The measurements were made in 20 mM sodium phosphate and 20 mM sodium acetate buffer for pH >2 and in dilute hydrochloric acid solution for pH<2 (0.06 M HCl and 0.1 M HCl for pH 1.7 and 1.1, respectively). Excess solid was equilibrated for 24 hours with stirring at 37⁰C. Samples were filtered through Millipore HV 0.45 µ m filters and supernatant was collected and concentration quantitated by HPLC. A calibration curve was used over a range of 0.2 -70 µ g/mL.
Permeability and Transporter Evaluations
Caco-2 Cell Permeability. Caco-2 cells were cultivated under aseptic conditions at 37 o C in an atmosphere of 90% relative humidity, 95% air and 5% CO 2 in culture medium consisting of D-MEM, 10% FBS, 1% penicillin/streptomycin solution and 1% MEM-NEAAin 175 cm 2 culture flasks and passaged when cells reached 75-85% confluency with Trypsin-EDTA solution (0.25%). Caco-2 cells at passages 30 through 50 were seeded onto Corning Costar 24-well cell culture devices (Sigma-Aldrich, St. Louis, MO). The 24-well cultures were maintained with medium being replaced every three to four days and used in experiments on days 21-23 postseeding. One day prior to the study, the base plate was exchanged for a fresh one and media was DMD #51193
changed. Cell monolayers were rinsed in HBSS, pH 7.4, and equilibrated in this buffer for 1 hour prior to experiments then the plates were placed on the deck of a Tecan Genesis robotic system (Tecan, Durham, North Carolina, USA). To begin the experiment, 300 µL of dosing solution was added to the apical (A) chamber for apical to basolateral (AB) or 750 µL to the basolateral (B) chamber for basolateral to apical (BA) transport studies with blank buffer added to the receiver chambers (800 µL or 300 µL for AB and BA studies, respectively). Samples were collected at five minutes and at two hours for donor and at one hour and two hours for receiver samples. The receiver chambers were replenished with fresh HBSS after the one hour sampling.
Donor samples were diluted 10x with fresh HBSS following collection. The samples were analyzed by LC-MS/MS. Following the study, cell monolayers were incubated for one hour with buffer containing 0.1 mg/ml Lucifer yellow (dosed on the apical side, monitor for appearance on the basolateral side) to verify monolayer integrity was not compromised during the study using a criteria of <1% transported.
MDR1-MDCK and BCRP-MDCK-LE Cell Permeability and Efflux Transport
Determination. The in vitro assessment of axitinib included the determination of efflux across monolayers of Madin Darby Canine Kidney (MDCK) cells transfected with human Multidrug
Resistance 1 gene (MDR1 or P-gp) and Breast Cancer Resistance Protein (BCRP). BCRP was transfected into MDCK cells that were selected for low expression of canine P-gp and is referred to as BCRP-MDCK-LE. MDCK-LE cells are a clonal isolate of MDCK wild-type cells selected for low background efflux activity (Di et al., 2011) . All cells were maintained similarly to Caco-2 cells described in the above section with the exceptions that these cells were grown on 96-well Millicell cell culture devices (Millipore, Billerica, MA) and maintained on media prepared with MEM-α supplemented with 1% MEM-NEAA, 1% Glutamax-I, 1% penicillin/streptomycin and This article has not been copyedited and formatted. The final version may differ from this version. analysis. Standard curves for axitinib and rosuvastatin were prepared in matrix utilizing excess suspended hepatocytes in order to calculate concentration values for each sample.
Caco-2 Digoxin IC 50 Determination. The inhibition of digoxin efflux across Caco-2 cell monolayers by axitinib was assessed using methods as described previously (Cook et al., 2010) .
Briefly, Caco-2 cells (passage 26) were plated in 24-well transwell plates containing 1 µm pore size inserts (Becton Dickinson, Cowley, U.K.), at a seeding density of 1.6 × 10 5 cells/mL and seeding volume of 250 µL. The assay was carried out on day 22 post seeding, with media replaced every other day. Trans-epithelial electrical resistance (TEER) levels were measured prior to the experiment to ensure monolayer integrity. The efflux of
determined after a 2 hour incubation in the presence of increasing concentrations of axitinib.
The same experiment was repeated using ketoconazole as a positive control inhibitor. IC 50 values were fitted as described in the Data Analysis section. Multiple reaction monitoring was used to detect the compounds using the following transitions (267→90, atenolol; 388→356, axitinib; 1203→86, cyclosporin A; 782→652, digoxin; 470→415, Ko143; 482→258, rosuvastatin; 364→309, talinolol; 422→378, topotecan). The peak area ratio of the analyte to the internal standard was determined for each injection and used to determine the biological response under consideration for the particular assay. Particle radius 2 µm, and Drug particle density 1.2 g/mL. GastroPlus™ simulation outputs estimated the dissolved axitinib mass (mg) at 0. 08, 0.16, 0.24, 0.88, 1.04, 2, 4, 6, 8, 10, and 12 hours post dose in the stomach, duodenum, jejunum 1 (upper), and jejunum 2 (lower) for each dosing condition. To provide a conservative estimation of intestinal concentration, the sum of dissolved compound in stomach contents, duodenum, jejunum 1 (upper), and jejunum 2 (lower) across a 12-hour time window were used to determine the amount of drug in solution and determine a maximum concentration in micromolar. The dissolved mass across the various GI regions was then summed to estimate the total dissolved mass at each time point and converted to concentration (µM). This was accomplished using the following equation:
BCRP-MDCK-LE
This provided the most conservative estimate of dissolved drug. were calculated as previously reported (Fenner et al., 2009 ). The drug interaction risk assessment was conducted according to the USFDA and EMA guidance documents (Anonomous, 2012c; Anonomous, 2012b 
Whole-Body Autoradiography in
Results
Solubility Determination
The equilibrium solubility characteristics of axitinib as a function of pH are shown in Figure 2 .
Axitinib is highly soluble at low pH but solubility declines rapidly as pH increases above 2.0. At the range near neutral pH, the solubility of axitinib was < 1 µM. A series of solubility studies were conducted in order to ensure transport study data were reported using concentration ranges where axitinib was in solution. Additional solubility studies were performed to simulate experimental conditions during transport studies. When 10 µM axitinib was prepared in 0.5 or 1% DMSO in HBSS buffer (pH 7.4), and incubated at 37°C for 3 hours, the resulting solution concentration was 4.2 ± 2.2 µM and 2.4 ± 0.5 µM (mean ±SD), respectively. When the equilibrium solubility of axitinib was determined in 0.5 or 1% DMSO in HBSS buffer (pH 7.4), the resulting solution concentration was 0.31 ± 0.02 µM and 0.38 ± 0.06 µM (mean ±SD),
respectively. This suggested that under the conditions used for transport studies, axitinib forms a supersaturated solution when solubilized using DMSO solvent even though the equilibrium solubility was considerably lower. Considering these results, data were reported for transport studies approximately up to 5 µM even though the experiments may have included higher concentrations.
Permeability and Efflux
The in vitro cellular permeability and efflux of axitinib was initially determined using Caco-2 cell monolayers. The Papp (AB), Papp (BA) and efflux ratio of axitinib (1 μ M) in Caco-2 cells was 17x10 -6 cm/s, 160x10 -6 cm/s and 9.7, respectively. This suggested that axitinib has high passive permeability with some efflux activity.
P-gp and BCRP Substrate Evaluation
This article has not been copyedited and formatted. The final version may differ from this version. Taken together results suggested that axitinib is a weak substrate of P-gp and is not a substrate of BCRP.
P-gp and BCRP Inhibition Evaluation
P-gp inhibition was evaluated in the Caco-2 monolayer cell line with digoxin as the probe substrate. This is an accepted model to evaluate P-gp inhibition according to regulatory guidance (Anonomous, 2012b) . The concentration range of axitinib in these studies ranged from 0.1 to 75 µ M but evaluation of inhibition above 7 µ M was limited, presumably due to poor solubility in pH 7.4 HBSS buffer. This resulted in inhibition curves not achieving maximal inhibition ( Figure 4A ). To better fit the inhibition curve, positive control inhibitor data for ketoconazole was utilized to define the maximum inhibition of digoxin flux ( Figure 4B ).
This article has not been copyedited and formatted. The final version may differ from this version. Determination of an IC 50 value for axitinib as described by Fenner and coworkers was then calculated from the resulting data (Fenner et al., 2009 ). Axitinib decreased P-gp mediated digoxin transport by 67% at 7 µM, resulting in an IC 50 value of 3.0 µM by utilizing ketoconazole to define maximum inhibition. BCRP inhibition was evaluated in BCRP-MDCK-LE cells with topotecan as the probe substrate at a concentration range from 0.032 to 20 µM. Above 20 µM axitinib compromised monolayer integrity was observed as evidenced by elevated Lucifer yellow permeability post-experiment (data not shown). Axitinib decreased BCRP mediated efflux of topotecan to a maximum of 49% of nominal efflux at 5.6 µM which did not decrease further at 10 or 20 µM presumably due to poor solubility ( Figure 5A ). Ko143, the positive control inhibitor of BCRP, completely inhibited topotecan efflux with an IC 50 of 0.08 µM ( Figure 5B ).
An IC 50 value of 4.4 µM for axitinib in BCRP mediated topotecan transport was estimated utilizing Ko143 to define maximum inhibition.
OATP1B1, OATP1B3 and OATP2B1 Evaluation
To determine whether axitinib is a substrate for human hepatic uptake transporters, OATP1B1, OATP1B3 and OATP2B1 in vitro uptake studies were performed. Axitinib (concentration range from 0.5 to 4 µ M) was not a substrate of OATP2B1 at any concentration evaluated. Axitinib, was a substrate for both OATP1B1 and OATP1B3 where OATP1B3 demonstrated an approximately 2-fold greater uptake rate than OATP1B1 (Table 3) .
Hepatocyte Suspension: Active Uptake Assay
The positive control hepatic uptake substrate rosuvastatin is transported by OATP1B1, OATP1B3, OATP2B1 and NTCP (Ho et al., 2006) and uptake into sandwich culture human hepatocytes is completely inhibited by rifamycin SV (100 µM), an inhibitor of OATPs and NTCP (Mita et al., 2006; Bi et al., 2012) . This system enables the functional evaluation of active This article has not been copyedited and formatted. The final version may differ from this version. nearly complete inhibition by rifamycin SV (100 µM) ( Figure 6 ). When axitinib was tested in the same system, compound accumulation into the hepatocytes reached a near maximum by 0.5 min and little additional uptake was observed by 1.5 min. Addition of rifamycin SV (100 µM)
did not inhibit axitinib uptake into hepatocytes. The results for axitinib indicated passive diffusion was the primary hepatic uptake mechanism at 1 µM.
GastroPlus™ Simulation of Axitinib Intestinal Concentrations and Efflux Transporter Drug Interaction Risk Assessment
Both USFDA and EMA regulatory guidance recommend the assessment of drug interaction risk for efflux transporters systemically and at the level of the gastrointestinal tract (Anonomous, 2012b; Anonomous, 2012c Regulatory guidance also requires a risk assessment for systemic interaction with efflux transporters. The USFDA and EMA guidance differ in the use of total maximum plasma concentration (C max ) or unbound plasma C max divided by IC 50 or K i the and a use of a safety factor of 10 or 50, respectively. The highest dose of axitinib administered clinically is 10 mg twice daily resulting in a mean total or unbound C max of 0.16 or 0.0008 µM, respectively (Rugo et al., 2005; Anonomous, 2012a) . The total or unbound [I 1 ]/IC 50 was less than 0.1 or 0.02, the respective thresholds for the USFDA and EMA DDI guidance, for efflux transporter inhibition.
Whole-Body Autoradiography in Mice
The tissue distribution of indicating rapid absorption and radioactivity was widely distributed in all tissues. The highest level of axitinib-derived radioactive equivalents was present in the gall bladder consistent with hepatic elimination of the drug (metabolism and transport). The radioactivity ratio in the gall bladder to blood at 1 hour post-dose was 24 while the next highest levels in the liver and stomach mucosa were 3.8 and 3.6, respectively. By 24 hours most tissues measured contained concentrations of radioactivity below the limit of quantification (BLQ) with the exception pigment containing tissues (skin and uveal tract). Low concentrations of radioactivity were detected in the brain. The brain to blood ratio was ~0.09 at 1 hour post dose and brain concentrations were BLQ at 4 hour post-dose.
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
Axitinib inhibits cellular VEGF receptor tyrosine kinase phosphorylation and targetmediated functional activity (Hu-Lowe et al., 2008) . It is a more selective inhibitor of VEGF receptor-1, -2 and -3, PDGFR and c-KIT than both sunitinib and sorafenib and has greater affinity for these targets (Goldstein et al., 2010) . Axitinib is a low molecular weight, lipophilic and weakly basic molecule with high permeability. Tyrosine kinase inhibitors, such as dasatinib, imatinib, gefitinib, sunitinib and lapatinib, possess similar molecular characteristics including multiple aromatic rings, similar molecular weight (ranging from 398-494 AMU), moderate hydrophobicity (logP values >2), and most are primarily cleared via metabolism by CYP3A4.
These chemical features are also typical for substrates of ABC transporters (Polli et al., 2008; Chen et al., 2009; Oostendorp et al., 2009; Shukla et al., 2009; Carcaboso et al., 2010) . Herein, we found that axitinib showed efflux in Caco-2 cells, was a weak substrate for human P-gp and was not a BCRP substrate using transfected cell lines. Axitinib is however an inhibitor of P-gp and BCRP. Axitinib inhibits VEGFR by forming a binding complex to the ATP catalytic binding site of the kinase domain (Bender, 2004; Solowiej et al., 2009) . It is not known if axitinib inhibits P-gp and BCRP by binding to the substrate or ATP binding site. Axitinib appeared to be a substrate for uptake by OATP1B1 and OATP1B3 in transfected cell systems.
However, additional hepatocyte uptake studies showed that the OATP inhibitor rifamycin SV did not have any impact on the uptake of axitinib under the same conditions where rosuvastatin uptake was markedly inhibited. Considering the physicochemical properties of axitinib, the high permeability and passive uptake into the hepatocyte, the results suggest that OATPs do not play a significant role in its hepatic disposition. While only OATPs were evaluated in this study and it appeared that passive uptake of axitinib into hepatocytes predominated the potential role of other This article has not been copyedited and formatted. The final version may differ from this version. uptake transporters was not evaluated in this study. Thus, considering the major uptake and efflux transporters evaluated it appears that transporters play a minor role in the absorption, distribution and excretion of axitinib in humans.
Our finding that axitinib is at most only a weak substrate for MDR1 and not a BCRP substrate is in contrast to the recent publication by Poller et al. (2011) , that identified axitinib as a good and moderate substrate for MDR1 and BCRP, respectively. We found that, over a concentration range of axitinib from 1 to 5 µ M, the P-gp mediated efflux ratio in the MDR1-MDCK was ≤ 1.45 while our positive control substrate, digoxin, exhibited an efflux ratio of 24.
BCRP efflux ratios of axitinib were near unity while the efflux ratio of our positive control, (2011) where parent drug was specifically measured. We confirmed their finding that axitinib has restricted mouse brain distribution since the level of axitinib radioactive equivalents present in the brain was markedly lower than whole blood or other tissues. Poller et al. (2011) went on to study the brain disposition of axitinib in abcg2 -/-, abcb1a/b -/-and in triple knockout mice. These results showed no effect of abcg2 -/-, a marked increase in brain exposure in abcb1a/b -/-and an even greater increase in the triple knockout. The ability of P-gp and bcrp to work together to limit brain disposition has also been described for lapatinib and dasatinib (Chen et al., 2009; Polli et al., 2009 ). The results of Poller et al. (2011) suggested that the mouse mdr1
limits the brain distribution of axitinib with the role of bcrp being unclear. While axitinib, like several other TKIs, exhibits poor CNS penetration in rodents, there is currently no information available for human CNS exposure following longer duration therapy with axitinib.
Axitinib is an inhibitor of MDR1 and BCRP in vitro with IC 50 values of 3 and 4.4
respectively. The assessment of drug interaction liability was based on the white paper on transporters in drug development (Giacomini et al., 2010) and most recent FDA and EMA drug interaction guidance documents (Anonomous, 2012b; Anonomous, 2012c) . Axitinib was below the guidance cutoff values for defining systemic drug interaction risk with efflux transporters.
However, [I 2 ]/IC 50 values were 35 and 24 for P-gp and BCRP, respectively, which exceeded the cutoff value of 10 when total administered dose was used to estimate the intestinal concentration.
As shown in Figure 2 , axitinib is highly soluble at low pH but solubility declines rapidly as pH increases above 2.0 which suggested that in the intestinal regions where efflux transporters are located and pH is more neutral, the solution concentration of axitinib achieved might be limited. diffusion is the main mechanism of entry into the hepatocyte when investigated at 1 µM. In early clinical trials with axitinib, variability in pharmacokinetics or drug exposure was observed.
Inter-subject variability has been associated with OATP1B1 genetic polymorphisms in patients taking various statins and irinotecan (Nozawa et al., 2005; Romaine et al., 2010) . Since axitinib showed some OATP1B1 substrate activity this observation led us to the hypothesis that an inactive phenotypic variant could be a factor in clinical PK variability. However, no significant association between the SLCO1B1 (T521C) genetic polymorphism and variability in axitinib plasma exposure was noted in a pooled analysis of 11 healthy volunteer studies during early clinical trials (Brennan et al., 2012) . Thus, it is likely that the observed high permeability of axitinib overrides any potential differences in active hepatic uptake that could be exhibited by phenotypic variants of these transporters. This observation highlights that, for a transporter to alter the disposition of a drug, the active transporter process must play a significant role relative to the passive contribution.
This article has not been copyedited and formatted. The final version may differ from this version. Tables   Table 1: Effect of increasing axitinib concentration on efflux transport in MDR1-MDCK monolayers. This observation is likely responsible for the permeability differences.
MDR1-MDCK
